Department of Medical Oncology, National Taiwan University Cancer Center, Taipei, Taiwan.
Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, Taipei, Taiwan.
Thorac Cancer. 2023 Aug;14(22):2216-2221. doi: 10.1111/1759-7714.14997. Epub 2023 Jun 20.
Immune checkpoint inhibitors (ICIs) have demonstrated efficacy in advanced esophageal squamous cell carcinoma (ESCC). Heterogeneous responses to ICIs have been reported previously. Here, we describe a patient with advanced ESCC exhibiting a response to durvalumab plus tremelimumab for more than 6 months except primary resistant esophageal tumor. The esophageal tumor had higher regulatory T cells, neutrophils, and mast cells scores estimated by NanoString platform than hepatic tumor. The immunohistochemistry study confirmed higher expression levels of Foxp3, and myeloperoxidase (MPO) in the esophageal tumor. The different immune contextures may underlie the heterogeneous responses to ICI combination in this ESCC patient.
免疫检查点抑制剂（ICIs）已在晚期食管鳞状细胞癌（ESCC）中显示出疗效。先前已有报道称对 ICI 的反应存在异质性。在这里，我们描述了一名晚期 ESCC 患者，在接受 durvalumab 和 tremelimumab 联合治疗超过 6 个月后，除了原发性耐药食管肿瘤外，对该治疗有反应。食管肿瘤的调节性 T 细胞、中性粒细胞和肥大细胞评分高于肝肿瘤，这是通过 NanoString 平台估计的。免疫组化研究证实了 Foxp3 和髓过氧化物酶（MPO）在食管肿瘤中的表达水平更高。不同的免疫微环境可能是导致该 ESCC 患者对 ICI 联合治疗反应异质性的原因。
